Inhibikase Therapeutics Dividend
What is Inhibikase Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Inhibikase Therapeutics Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (IKT)||n/a|
Notable Dividend: Unable to evaluate IKT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IKT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IKT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IKT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IKT has not reported any payouts.